Bookmark and Share
Phenylalanine (CID 994) - Compound BioActivity Data
.
BioActivity Outcomes:
Active(1)
 
 
Inactive(142)
 
 
Inconclusive(5)
 
 
Unspecified(26)
 
 
Top Targets:
NR LBD ER(7)
 
 
 
NR LBD AR(7)
 
 
NR LBD GR(4)
 
 
NR LBD TR(3)
 
 
p450(2)
 
 
 
BioAssay Types:
Confirmatory(108)
 
 
 
Literature(28)
 
 
 
Summary(15)
 
 
 
Screening(3)
 
 
BioActivity Types:
Potency(62)
 
 
 
Data download

Chemical Probe    Active    Inactive    Inconclusive    Unspecified   

Total Bioassays: 172    Data Row: 174   Total Pages: 9   Display: Page     
Sort: [Click the result table header to sort]
#SubstanceActivityBioAssayTargetLinks
OutcomeTypeValue [μM]
1
[SID48416422]
DSSTox (FDAMDD) FDA Maximum (Recommended) Daily Dose Database [AID1195, Type: other]
View
2
[SID103194122]
Km 740.5TP_TRANSPORTER: uptake in Xenopus laevis oocytes [AID681145, Type: Literature]SLC16A10 protein [gi:121945115]
View
3
[SID103194122]
Compound was evaluated for antisickling activity, and ratio was calculated as solubility HbS compound (g/dL) / solubility HbS control(g/dL) at a concentration of 40 mM (for 173 assays) [AID231855, Type: Literature]
View
4
[SID103194122]
Evaluated for antisickling activity, and ratio was calculated as solubility HbS (g/dL) / solubility HbS control(g/dL) at a concentration of 10 mM [AID231856, Type: Literature]
View
5
[SID103194122]
Evaluated for antisickling activity, and ratio was calculated as solubility HbS (g/dL) / solubility HbS control(g/dL) at a concentration of 20 mM [AID231857, Type: Literature]
View
6
[SID103194122]
Evaluated for antisickling activity, and ratio was calculated as solubility HbS (g/dL) / solubility HbS control(g/dL) at a concentration of 5 mM [AID231858, Type: Literature]
View
7
[SID103194122]
Evaluated for antisickling activity, and ratio was calculated as solubility HbS compound (g/dL) / solubility HbS control(g/dL) at a concentration of 40 mM [AID231859, Type: Literature]
View
8
[SID103194122]
Solubility assay expressed as [HbSdrug/HbS control] at 10 mM concentration [AID21129, Type: Literature]
View
9
[SID103194122]
Solubility assay expressed as [HbSdrug/HbS control] at 20 mM concentration [AID21130, Type: Literature]
View
10
[SID103194122]
Solubility assay expressed as [HbSdrug/HbS control] at 40 mM concentration [AID21131, Type: Literature]
View
11
[SID103194122]
Solubility assay expressed as [HbSdrug/HbS control] at 5 mM concentration [AID21132, Type: Literature]
View
12
[SID103194122]
Solubility of Deoxyhemoglobin S (dHbS) concentration after addition dithionite as control [AID21143, Type: Literature]
View
13
[SID103194122]
Solubility of Haemoglobin S (HbS) concentration after addition of acid and dithionite [AID21145, Type: Literature]
View
14
[SID103194122]
Solubility ratio ([HbS+drug (10 mM)]/[HbS-drug]) [AID22012, Type: Literature]
View
15
[SID103194122]
Solubility ratio ([HbS+drug (20 mM)]/[HbS-drug] [AID22013, Type: Literature]
View
16
[SID103194122]
Solubility ratio ([HbS+drug (40 mM)]/[HbS-drug]) [AID22148, Type: Literature]
View
17
[SID103194122]
Solubility ratio ([HbS+drug (5 mM)]/[HbS-drug]) [AID22149, Type: Literature]
View
18
[SID103194122]
Maximal activatory effect against human carbonic anhydrase II (hCA II) [AID47718, Type: Literature]
View
19
[SID103194122]
Maximal activatory effect against human carbonic anhydrase I (hCA I) [AID50341, Type: Literature]
View
20
[SID103194122]
Evaluated for antisickling activity, and initial HbS concentration was reported, values from different experiments (no. of runs=2) [AID85631, Type: Literature]
View